Mayo Clinic maps zombie cells and finds new ways to quiet them
Seven Mayo Clinic studies reveal why senescent cells fuel inflammation and test new ways to target them, including a tomato compound that helped aging mice.
Summary
Senescent cells, often called zombie cells, stop dividing but stay active and release inflammatory signals that contribute to age-related disease. Mayo Clinic scientists published seven studies in Nature journals that look at how to recognize different types of these cells, why they drive inflammation and how to dampen their effects. The work shows senescent cells are far more varied than once thought, differing by tissue and by what triggered them. The team built the SenMayo gene set, a gene-activity signature that spots senescent cells across tissues, and tested it in bone biopsies from older adults. Other studies point to a link between mitochondria and chronic inflammation. In aging mice, experimental treatments, including a natural compound found in tomatoes, reduced inflammation and improved physical and brain health. These are early findings in animals and in lab systems, but they lay groundwork for therapies that target specific harmful cells rather than all senescent cells at once.
Detailed Summary
Senescent cells, nicknamed zombie cells, no longer divide yet remain metabolically active. They secrete inflammatory molecules that can damage neighboring tissue and contribute to diseases of aging. Removing or calming them is one of the most closely watched strategies in longevity science, but progress has been slowed by a basic problem: scientists have struggled to identify these cells reliably.
Seven studies from Mayo Clinic's Robert and Arlene Kogod Center on Aging, published in Nature journals, address that problem directly. They show that senescent cells are heterogeneous. Their features change with their location in the body and with the stress that pushed them into senescence. To help sort them out, the team created SenMayo, a gene set that uses patterns of gene activity to flag senescent cells consistently across tissues and experimental systems. It was tested in bone biopsies from older adults, and the signature faded after senescent cells were cleared in preclinical experiments. SenMayo is now widely used in aging research.
Other studies examined why these cells produce persistent inflammation, pointing to a hidden connection between mitochondria and chronic inflammatory signaling. In aging mice, experimental treatments reduced inflammation and improved physical and brain health. One approach used a natural compound found in tomatoes. The work also feeds into the NIH-funded SenNet Consortium, which is building maps of senescent cells across human tissues and across the lifespan.
For readers, the main message is that future therapies are likely to be more precise. Rather than treating all senescent cells alike, researchers hope to target the specific subtypes that drive dysfunction in particular tissues. That could mean fewer side effects and better results than broad approaches.
Caveats matter. The therapeutic results come from mice, and the tomato compound has not been shown to slow human aging. Eating tomatoes is not a proven senescence treatment. The news summary also omits doses, sample sizes and effect sizes, so the primary papers should be consulted before drawing conclusions about human benefit.
Key Findings
- Senescent cells vary widely by tissue and by trigger, so they cannot be treated as one uniform population.
- The SenMayo gene set identifies senescent cells across tissues and was validated in bone biopsies from older adults.
- Its signature declined after senescent cells were removed in preclinical experiments, supporting its use as a marker.
- In aging mice, experimental treatments, including a tomato-derived compound, reduced inflammation and improved physical and brain health.
- Findings support SenNet's effort to map senescent cells across human tissues over a lifetime.
Methodology
This is a university press release republished by ScienceDaily, summarizing seven studies published in Nature journals. Mayo Clinic is a credible research source, but the article is a secondary summary. Evidence combines human bone biopsies, preclinical experiments and aging mouse models.
Study Limitations
Therapeutic benefits were shown in mice, and the excerpt gives no doses, sample sizes or effect sizes. The tomato compound is not named, and its human relevance is unknown. Consult the primary papers for methods and data.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: